A total of 86 (63.7%) patients with wild/wild tumours and five (33.3%) patients with BRAF mutation-positive tumours received anti-EGFR therapy, whereas few patients with KRAS12 or KRAS13 mutations received anti-EGFR therapy (1.9% and 3.8%, respectively). Here, BRAF is linked to neoplasm.